Testing effectiveness (Phase 2)Study completedNCT01704703
What this trial is testing
Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques
Who this might be right for
Stage IV Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 72